185 related articles for article (PubMed ID: 23942070)
1. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.
Hitre E; Budai B; Takácsi-Nagy Z; Rubovszky G; Tóth E; Remenár É; Polgár C; Láng I
Br J Cancer; 2013 Sep; 109(5):1117-22. PubMed ID: 23942070
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
[TBL] [Abstract][Full Text] [Related]
3. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
4. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
[TBL] [Abstract][Full Text] [Related]
5. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
6. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Chen Y; Wu X; Bu S; He C; Wang W; Liu J; Guo W; Tan B; Wang Y; Wang J
Cancer Sci; 2012 Nov; 103(11):1979-84. PubMed ID: 22845557
[TBL] [Abstract][Full Text] [Related]
7. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.
Zhao C; Miao J; Shen G; Li J; Shi M; Zhang N; Hu G; Chen X; Hu X; Wu S; Chen J; Shao X; Wang L; Han F; Mai H; Chua MLK; Xie C
Ann Oncol; 2019 Apr; 30(4):637-643. PubMed ID: 30689735
[TBL] [Abstract][Full Text] [Related]
8. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Kim C; Lee JL; Ryu MH; Chang HM; Kim TW; Lim HY; Kang HJ; Park YS; Ryoo BY; Kang YK
Invest New Drugs; 2011 Apr; 29(2):366-73. PubMed ID: 19997960
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.
Zhang X; Du L; Zhao F; Wang Q; Yang S; Ma L
Int J Biol Sci; 2016; 12(4):446-53. PubMed ID: 27019628
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Baselga J; Gómez P; Greil R; Braga S; Climent MA; Wardley AM; Kaufman B; Stemmer SM; Pêgo A; Chan A; Goeminne JC; Graas MP; Kennedy MJ; Ciruelos Gil EM; Schneeweiss A; Zubel A; Groos J; Melezínková H; Awada A
J Clin Oncol; 2013 Jul; 31(20):2586-92. PubMed ID: 23733761
[TBL] [Abstract][Full Text] [Related]
12. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
15. RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.
Jensen AD; Krauss J; Weichert W; Debus J; Münter MW
Radiat Oncol; 2010 Nov; 5():102. PubMed ID: 21047402
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
Olivatto LO; Vieira FM; Pereira BV; Victorino AP; Bezerra M; Araujo CM; Erlich F; Faroni L; Castro L; Lusis EC; Marins A; Ferreira CG
Cancer; 2013 Aug; 119(16):2973-80. PubMed ID: 23674135
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.
Farley J; Sill MW; Birrer M; Walker J; Schilder RJ; Thigpen JT; Coleman RL; Miller BE; Rose PG; Lankes HA
Gynecol Oncol; 2011 May; 121(2):303-8. PubMed ID: 21329967
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Schuster T; Porschen R; Al-Batran SE; Hofheinz R; Thuss-Patience P; Moehler M; Grabowski P; Arnold D; Greten T; Müller L; Röthling N; Peschel C; Langer R; Lordick F
Ann Oncol; 2009 Oct; 20(10):1667-73. PubMed ID: 19549707
[TBL] [Abstract][Full Text] [Related]
20. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
